Abacavir/lamivudine
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Abacavir | Nucleotide analogue reverse transcriptase inhibitor |
| Lamivudine | Nucleotide analogue reverse transcriptase inhibitor |
| Clinical data | |
| MedlinePlus | a696011 |
| Pregnancy cat. | C (US) |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| ATC code | J05AR02 |
| PubChem | CID 5273759 |
| NIAID ChemDB | 225604 |
 (what is this?) (verify) |
|
Abacavir/lamivudine (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom.[1] It is a fixed dose combination of lamivudine (3TC, Epivir) and abacavir (ABC, Ziagen).
Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.
References [edit]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
